Addyi vs Testosterone for Women: Which Low-Libido Option Actually Fits?

Addyi is usually the cleaner first conversation for women under 65 whose main problem is acquired, generalized low desire and who want a non-hormonal, FDA-approved option. Testosterone is usually the better conversation when low desire is part of a bigger menopause or hormone picture — but in the U.S. it's off-label for women and needs lab checks and monitoring. There's no universal "winner," because they're built for different people.

Here's the fast comparison. We go deeper on every row below.

Where you are in the menopause journey is the biggest factor here. Before menopause, Addyi (or the on-demand option, Vyleesi) is the FDA-approved route, and testosterone isn't a first-line choice — the evidence just isn't strong there yet. After menopause, both are real options, and the choice comes down to hormone vs. non-hormone, side effects, and how comfortable you are with off-label care. Menopause is the point when your periods have stopped for 12 months; perimenopause is the bumpy few years before that.

And here's the freshness most articles miss: in December 2025, the FDA updated Addyi's label to cover women under 65 with acquired, generalized HSDD. Older pages still say "premenopausal only." That's out of date.

Addyi is a nightly, non-hormonal pill for a specific kind of low desire. Testosterone is a hormone, usually considered as part of menopause care, and in the U.S. it has no FDA-approved version for women. One works on brain chemistry; the other is a hormone used at a low, monitored dose when HSDD fits.

Both help some women, but neither is dramatic. In the trials behind Addyi's approval, women on it had about 1/2 to 1 more satisfying sexual event per month than women on a placebo. Testosterone shows a similar bump — about 1 more per month — in postmenopausal women. These are real, measurable changes, not overnight transformations.

Here's the honest part most pages skip: neither Addyi nor testosterone is a switch that turns your sex drive back on. In the trials, each added only about one satisfying encounter a month over a placebo — and neither works for everyone. If you're picturing an overnight fix, both will let you down.

But here's why that should make your decision easier, not harder: since there's no clearly stronger drug, the smart move isn't chasing the one with more buzz. It's getting matched to the option that fits your menopause stage and health — with a clinician who checks in at the 8-week mark and switches you if it's not working. That's how you avoid burning three months (and real money) on the wrong path.

And a smaller, product-level honesty: Addyi is not an on-demand pill. If you want something you take only before sex, Addyi is the wrong tool — ask about Vyleesi instead. But because Addyi works slowly and steadily, it fits the kind of low desire that's there all the time, not just in the moment.

No. Unlike men, women don't have a blood-testosterone number that diagnoses low libido or predicts who will respond. The "under 300 ng/dL" figure you'll see quoted is a men's guideline — it does not apply to women. For women, testosterone for low desire is a carefully monitored trial, and blood tests are used to keep the dose from going too high, not to qualify you.

This trips up a lot of pages — and a lot of blood-work upsells. There's no proven link between a specific testosterone level and low desire in women. So a good clinician doesn't hand you testosterone because a lab number looks "low." They consider it because your symptoms fit HSDD, and then use labs to keep you in a safe, normal-for-women range. If a provider says your libido problem is because your testosterone is "below 300," that's a male cutoff in the wrong place.

There is no FDA-approved testosterone product for women in the U.S. Testosterone is also a Schedule III controlled substance. Clinicians can still prescribe it — either off-label (an approved male product at a much lower dose) or as a compounded version mixed by a pharmacy — and major medical groups support a careful trial for postmenopausal HSDD.

Three terms worth knowing, because providers use them loosely:

• FDA-approved means the exact product was tested and cleared by the FDA for a specific use. No testosterone fits this for women.
• Off-label means using an FDA-approved product (like a men's testosterone gel) for a use or dose it wasn't officially approved for. This is legal and common, and it's how a lot of careful testosterone prescribing for women is done — a small fraction of the male dose.
• Compounded means a pharmacy mixes a custom version (say, a cream at a woman-sized strength). Per the FDA, compounded drugs are not FDA-approved, and the FDA does not verify their safety, effectiveness, or quality before they're sold.

Here's the nuance most affiliate pages bury: leading sexual-medicine guidelines (ISSWSH) say compounded testosterone can't be recommended because there isn't enough data on how consistent or safe it is, and they favor a low, monitored dose of an approved product. That doesn't make compounded testosterone forbidden — plenty of women use it with good clinician oversight — but you deserve to know which one you're being offered, and to ask why.

Neither is clearly "safer" — the risks are just different, and which matters more depends on you. Addyi's main issues are alcohol timing, fainting/low blood pressure, sleepiness, and a few drug and liver interactions. Testosterone's main issues are acne, extra hair, a possible voice change if the dose runs too high, and the fact that long-term safety in women isn't fully settled.

Through telehealth, Addyi runs about $149 a month cash (as little as $40 a year with eligible commercial insurance, or $20 a month with a GoodRx coupon), with no generic yet. Midi's compounded testosterone cream is listed at about $100 for a 90-day supply — roughly $33 a month — before visit and lab costs, and insurance rarely covers testosterone for women.

Addyi is available through medication-specific telehealth routes tied to its manufacturer. Testosterone is more state- and provider-dependent because it's a controlled hormone that needs an exam, labs, and monitoring — so the better online model is real menopause care, not an instant prescription.

On the Addyi side: we don't push a specific partner here, because the honest first move for most women is confirming that acquired, generalized HSDD is really what's going on — not chasing a prescription. Start with Find My HRT Path; it'll tell you whether an HSDD-medication conversation is your best next step or whether something else fits better.

On the testosterone side: among the providers we track, here's how they line up for this specific need.

Sometimes a clinician uses both, because they act on different systems — Addyi on brain chemistry, testosterone as a hormone. But combining them shouldn't be a do-it-yourself decision or a "more is better" move. It only makes sense with a clear plan and monitoring.

There's no guideline-backed default that says to combine them, so if a clinician suggests both, ask:

• "Which problem are we treating with each one?"
• "What improvement should I expect, and by when?"
• "How will we know which one is helping — or causing a side effect?"
• "Do any of my medications, my alcohol use, or my liver history make this risky?"

The most useful thing you can do before a consult isn't asking for a specific drug — it's asking which pattern of low desire you have. A good clinician will separate HSDD, menopause symptoms, pain, medication effects, sleep, mood, and relationship factors before recommending Addyi, testosterone, or something else.